Pfizer Inc. (NYSE:PFE) Shares Sold by Alberta Investment Management Corp

Alberta Investment Management Corp decreased its holdings in Pfizer Inc. (NYSE:PFE) by 95.2% in the fourth quarter, HoldingsChannel.com reports. The firm owned 28,160 shares of the biopharmaceutical company’s stock after selling 559,997 shares during the quarter. Alberta Investment Management Corp’s holdings in Pfizer were worth $747,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the business. Strata Wealth Advisors LLC raised its holdings in Pfizer by 34.6% in the 4th quarter. Strata Wealth Advisors LLC now owns 15,162 shares of the biopharmaceutical company’s stock worth $402,000 after purchasing an additional 3,897 shares during the period. Convergence Investment Partners LLC increased its stake in Pfizer by 673.9% during the 4th quarter. Convergence Investment Partners LLC now owns 107,413 shares of the biopharmaceutical company’s stock worth $2,850,000 after buying an additional 93,533 shares in the last quarter. Plan Group Financial LLC increased its stake in Pfizer by 14.3% during the 4th quarter. Plan Group Financial LLC now owns 35,789 shares of the biopharmaceutical company’s stock worth $949,000 after buying an additional 4,472 shares in the last quarter. Allied Investment Advisors LLC increased its stake in Pfizer by 1.4% during the 4th quarter. Allied Investment Advisors LLC now owns 262,737 shares of the biopharmaceutical company’s stock worth $6,970,000 after buying an additional 3,534 shares in the last quarter. Finally, Bank of Jackson Hole Trust purchased a new stake in Pfizer during the 4th quarter worth approximately $264,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have commented on PFE shares. Guggenheim reiterated a “buy” rating and set a $33.00 price objective on shares of Pfizer in a research note on Monday, February 10th. Evercore ISI upgraded Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. Bank of America reiterated a “neutral” rating and set a $29.00 price objective on shares of Pfizer in a research note on Tuesday, December 10th. UBS Group dropped their price target on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. Finally, Citigroup dropped their price target on Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Trading Up 1.6 %

PFE opened at $26.32 on Friday. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54. The stock has a market capitalization of $149.14 billion, a PE ratio of 18.66, a P/E/G ratio of 0.64 and a beta of 0.64. The business’s 50 day moving average price is $26.30 and its 200 day moving average price is $27.41. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. During the same period in the prior year, the firm posted $0.10 earnings per share. The firm’s quarterly revenue was up 24.7% on a year-over-year basis. As a group, equities research analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.54%. This is a boost from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. Pfizer’s dividend payout ratio is 121.99%.

Insiders Place Their Bets

In related news, Director Ronald E. Blaylock acquired 19,457 shares of Pfizer stock in a transaction dated Thursday, February 13th. The shares were acquired at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the purchase, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 0.06% of the stock is owned by insiders.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.